A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)

NCT05394350 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

27

Enrollment

INDUSTRY

Sponsor class

Stopped Business Reasons

Conditions

Advanced Solid Tumors

Interventions

DRUG: MK-1088
BIOLOGICAL: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC